NCT06436248Recruiting
Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
The overall goal of the Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer (PROMISE) study is to better understand how women may incorporate both polygenic risk score (PRS) and novel early detection strategies in their decisions regarding cancer screening and risk reducing surgery. This study will conduct qualitative interviews to better understand women's attitudes regarding polygenic risk score (PRS) and early detection assays.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 24 (estimated)
- First submitted
- 29 Apr 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Ovarian cancer
- NCT number
- NCT06436248
What you commit to
- Study type: Observational
- Planned participants: 24
- From 1 Jul 2024 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous receipt of any prophylactic oophorectomy
Other illness
- Personal history of ovarian cancer
- Major psychiatric illness or cognitive impairment that in the judgment of the study investigators would preclude study participation.
Other
- Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.
Who the study is looking for
- Female, age 25 or older (given that women under this age are not generally recommended to receive BRCA1/2 genetic testing)
- Completed full sequence or targeted genetic testing with a clinically confirmed BRCA1 or BRCA2 deleterious mutation identified.
- English-fluent; the surveys and interviews were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.
Age in the registry: 25 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.